APAC Biotechnology Market Accelerates with New Investments

APAC Biotechnology Market Size, Dynamics and Key Players with Forecast

The APAC biotechnology market size is calculated at US$ 372.23 billion in 2024, grew to US$ 432.72 billion in 2025, and is projected to reach around US$ 1611.67 billion by 2034. The market is expanding at a CAGR of 14.80% between 2025 and 2034. 

The availability of capital is a major factor driving the APAC biotechnology market. Governments and corporate investors in the area have made significant investments in biotech in recent years, seeing the industry's potential for expansion and innovation. Precision medicine's expansion is another element propelling biotech investment in the APAC area. Proteomics, genetics, and other advances have made it possible for researchers to create more specialised treatments. Lastly, technological developments are also propelling biotech investment in the Asia-Pacific area.

Key Takeaways

• APAC biotechnology sector pushed the market to USD 372.23 billion by 2024.
• Long-term projections show USD 1611.67 billion valuation by 2034.
• Growth is expected at a steady CAGR of 14.80% in between 2025 to 2034.
• The biotechnology market is projected to grow from USD 1,744.83 billion in 2025 to USD 5,036.46 billion by 2034 at a CAGR of 12.5%.
• China held the major revenue of 35% of the APAC biotechnology market in 2024.
• Southeast Asia is estimated to grow at the fastest CAGR during the forecast period.
• By product/service, the biopharmaceuticals segment dominated the market in 2024, with a revenue of approximately 41%.
• By product/service, the bioservices segment is expected to grow at the fastest CAGR during the forecast period.
• By technology, the DNA sequencing & genomics segment dominated the market in 2024, with a revenue of approximately 28%.
• By technology, the CRISPR & gene editing segment is expected to grow at the fastest CAGR during the forecast period.
• By application, the healthcare/medical biotechnology segment dominated the market in 2024, with a revenue of approximately 46%.
• By end-user, the pharma & biotech segment dominated the APAC biotechnology market in 2024, with a revenue of approximately 44%.
• By end-user, the CROs & CDMOs segment is expected to grow at the fastest CAGR during the forecast period.

Key Indicators and Highlights

How is Biotechnology Growing in the APAC?

The APAC biotechnology market encompasses biopharmaceuticals, bioagriculture, bioindustrial applications, and bioservices across Asia-Pacific. It is one of the fastest-growing biotechnology markets globally, driven by strong government support (China’s “Made in China 2025,” India’s “Biotechnology Industry Research Assistance Council (BIRAC),” Japan’s regenerative medicine initiatives, and South Korea’s bioeconomy plan), expanding healthcare demand, large patient pools, and rising investments in biologics, cell & gene therapy, biosimilars, and agricultural biotech. The region is becoming a hub for clinical trials, outsourcing, and contract manufacturing due to cost advantages and advanced R&D clusters.

APAC Biotechnology Market Outlook

• Industry Growth Overview: In 2025, the biotech and life science employment market in Asia-Pacific is growing thanks to significant government assistance and private investment. Despite global challenges, development is driven by Australia's innovation environment and India's enormous talent pool, while major centres like China and Singapore are seeing spikes in biomanufacturing and R&D employment.
• Major Investors: The Chinese government and private sector, multinational pharmaceutical behemoths like Pfizer and AstraZeneca, and venture capital companies like ARCH Venture Partners, OrbiMed, and Novo Holdings are some of the major investors in the APAC biotechnology business.
• Startup Ecosystem: After a challenging 2024, the Asia-Pacific (APAC) biotechnology startup ecosystem is rebounding with renewed investor interest and investment, with an emphasis on fields including gene therapy, oncology, and AI-driven drug development. APAC's leading biotech companies include Singapore's Albatroz Therapeutics (therapeutic antibodies), China's CARsgen Therapeutics (CAR-T treatments) and Stemirna Therapeutics (mRNA platforms), and India's Pandorum Technologies (tissue engineering) and Bioprime Agri Solutions (bio-stimulants).

What is the Role of AI in the APAC Biotechnology Market?

AI's application in biology has grown in popularity recently. In order to get better, quicker, and more accurate outcomes, the biotech sector is rethinking its operations with AI and ML technologies. AI and biotech are paving the way for further breakthroughs and improvements in a variety of fields including pharmaceuticals, healthcare, animal husbandry, and agriculture. AI's contribution to biotechnology extends beyond data flow organisation and repetitive task automation. Research, daily tasks, data analytics, medication production, and many more areas can benefit from artificial intelligence.

What are Government Initiatives in the APAC Biotechnology Market?

• In September 2025, to strengthen its bioeconomy and spur innovation in industries including health, agriculture, and energy, the Indian government established a network of cutting-edge biomanufacturing centres. Under the BioE3 Policy, this programme gives researchers and businesses access to cutting-edge resources and infrastructure. India wants to become a global leader in biotechnology and develop a bioeconomy of USD 300 billion by 2030.
• In January 2025, in an effort to improve its competitiveness in the fast changing biotech sector, South Korea established a national biotechnology committee.
• In May 2024, in an effort to lower healthcare expenses related to late-stage diseases and enhance the quality of life for the local population, a Thai minister announced the opening of a new scientific study programme in Thailand in collaboration with China's top genomic research organisation.

Indian DBT National Fellowships

Segmental Insights

Why did the Biopharmaceuticals Segment Dominate the Market in 2024?

By product/service, the biopharmaceuticals segment was dominant in the APAC biotechnology market in 2024, accounting for approximately 41% of the revenue. One of the most significant developments in contemporary medicine is biopharmaceuticals. They are changing the medical landscape by providing extremely effective and focused therapies for a variety of ailments. Biotechnology breakthroughs and the identification of novel therapeutic targets are driving the continued fast evolution of biopharmaceuticals.

By product/service, the bioservices segment is estimated to experience the highest CAGR during the forecast period. CROs, CMOs, and CDMOs play a crucial role in the biotechnology industry's product development process and go beyond being merely outsourced partners. They actively collaborate in the field of scientific research because of their knowledge, ongoing creativity, and flexibility, which greatly aids in the success of their sponsor.

Which Technology Segment Dominated the Market in 2024?

By technology, the DNA sequencing & genomics segment was dominant in the APAC biotechnology market in 2024, with a revenue of approximately 28%. Real-time sequencing of complete genomes in clinical settings may be made possible by future developments that result in ever quicker, less expensive, and more precise sequencing techniques. The creation of portable sequencers may provide access to DNA sequencing in isolated locations or during infectious disease epidemics. Our knowledge of biology has been drastically altered by DNA sequencing, which has also created a plethora of new opportunities in biotechnology, research, and medicine.

By technology, the CRISPR & gene editing segment is estimated to experience the highest CAGR during the forecast period. With uses in the biotechnology, healthcare, and agricultural sectors, CRISPR is a new gene-editing technique that offers a precise, efficient, and effective alternative to genetic engineering. CRISPR holds great promise for improving food security, revolutionising medical treatments, and even assisting in the creation of biofuel.

Which Application Segment was Dominant in the Market in 2024?

By application, the healthcare/medical biotechnology segment was dominant in the APAC biotechnology market in 2024, accounting for approximately 46% of the revenue. A number of novel methods for illness prevention, diagnosis, and treatment have been developed as a result of the medical biotechnology field's recent explosive expansion. Polymerase chain reaction, gene sequencing, fluorescence in situ hybridization, microarrays, cell culture, genome editing, gene silencing with interference RNA, and other novel techniques have all made substantial contributions to the advancement of health research.

What Made the Pharma & Biotech Segment Dominant in the Market in 2024?

By end-user, the pharma & biotech segment was dominant in the APAC biotechnology market in 2024, accounting for approximately 44% of the revenue. The Asia Pacific region is making significant progress towards becoming a worldwide centre for biotechnology, despite mounting economic uncertainty. On the one hand, there is the incorporation of ongoing breakthroughs, technical adaptations, and prospective R&D expenditures. However, biotech firms are able to adjust to new technologies thanks to a surge of private capital and expanding government subsidies in the area.

By end-user, the CROs & CDMOs segment is estimated to experience the highest CAGR during the forecast period. CDMOs and CROs are not only players; they are innovators. These adaptable partners offer a range of vital benefits to different phases of biotechnology, going beyond simply serving as an outsourcing solution. They are the forces behind cost-cutting, the entry points to specialised knowledge, the force behind production scalability, and the catalysts in the sprint from laboratory to market. The key to turning concepts into practical, marketable health solutions is CDMOs.

Regional Insights

What are the Market Trends in China?

China captured a revenue share of 35% of the APAC biotechnology market in 2024. Chinese pharmaceutical companies, who have advanced from their copycat days to threaten Western innovation dominance, are driving a seismic change in the biotechnology sector. According to an exclusive Bloomberg News research, the number of new medications being developed in China for conditions including cancer, weight loss, and more soared to over 1,250 last year, far exceeding the European Union's total and almost catching up to the US's figure of over 1,440.

What are the Market Trends in Southeast Asia?

Southeast Asia is estimated to host the fastest-growing APAC biotechnology market during the forecast period. Due to rising collaboration and government initiatives.

In July 2025, in order to promote innovation in biotechnology for future food and artificial intelligence (AI) for healthy ageing, the New Zealand government has established two new collaborative research initiatives with Singapore. The programme, which is funded by MBIE's Catalyst Fund, will spend up to $24 million over three years in seven cooperative initiatives.

In May 2025, Nuevocor, an IND-stage biotechnology business based in Singapore that is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, reported that its US$45 million Series B fundraising was successfully completed.

Global Biotechnology Market Growth

The biotechnology market is projected to grow from USD 1,744.83 billion in 2025 to USD 5,036.46 billion by 2034, reflecting a CAGR of 12.5% over the forecast period, driven by continuous innovation and technological advancements in the industry.

Top Vendors in the APAC Biotechnology Market & Their Offerings

• WuXi AppTec: From drug discovery to commercialisation, WuXi AppTec is a leading contract research, development, and manufacturing organisation (CRDMO) offering services in all areas of drug development. Its services help businesses all around the world create drugs and healthcare goods more quickly.
• WuXi Biologics: A worldwide contract research, development, and manufacturing organisation (CRDMO), WuXi Biologics offers biopharmaceutical firms comprehensive services. It assists partners in the discovery, development, and production of biologics for a variety of illnesses, including vaccines and antibodies.
• BeiGene: BeiGene, a multinational biotechnology business that was recently relaunched as BeOne Medicines, is dedicated to creating novel and reasonably priced cancer medicines, particularly in the areas of immuno-oncology and targeted therapies.
• Innovent Biologics: Chinese biopharmaceutical business Innovent Biologics is well-known for its comprehensive platform for finding, creating, producing, and distributing new, high-quality medications. The business is a driving force in the Chinese biotech sector, developing novel therapies for immunological, metabolic, and oncological conditions.
• Samsung Biologics: Leading contract development and manufacturing organisation (CDMO) Samsung Biologics provides comprehensive services for creating and manufacturing biopharmaceutical goods. Its efforts and products are mostly concentrated on assisting multinational biotech and pharmaceutical businesses in effectively and consistently bringing novel therapies to market.

Top Companies in the APAC Biotechnology Market

• WuXi AppTec (China)
• WuXi Biologics (China)
• BeiGene (China)
• Innovent Biologics (China)
• Samsung Biologics (South Korea)
• Celltrion (South Korea)
• SK Biopharmaceuticals (South Korea)
• Takeda Pharmaceutical (Japan)
• Astellas Pharma (Japan)
• Fujifilm Diosynth Biotechnologies (Japan)
• Daiichi Sankyo (Japan)
• Bharat Biotech (India)
• Serum Institute of India
• Biocon Biologics (India)
• Dr. Reddy’s Laboratories (India, biosimilars)
• CSL Limited (Australia)
• Seegene (South Korea, molecular diagnostics)
• GenScript Biotech (China)
• Zai Lab (China)
• Chugai Pharmaceutical (Japan, Roche subsidiary)

Recent Developments in the APAC Biotechnology Market

• In June 2025, AN Ventures Partners, a firm that makes investments in the biotechnology sector, has signed an investment agreement with Sumitomo Mitsui Banking Corporation (SMBC).
• In March 2025, according to a statement from the firm, Bharat Biotech International Limited (BBIL), a participant in the creation of reasonably priced domestic vaccines, has announced its entry into the manufacturing of viral vectors and cell and gene therapy (CGT) at Genome Valley. Beyond developing vaccines, the business wants to develop customised and regenerative therapeutics to give millions of people fresh hope.

Segments Covered in the Report

By Product/Service

• Biopharmaceuticals (mAbs, vaccines, biosimilars, CGT)
• Bioinformatics
• Bioagriculture (GM crops, agri-bio inputs)
• Bioindustrial (enzymes, biofuels, biomaterials)
• Bioservices (CRO, CDMO)

By Technology

• DNA Sequencing & Genomics
• Fermentation & Cell Culture
• Tissue Engineering & Regenerative Medicine
• CRISPR & Gene Editing
• Nanobiotechnology
• Others (proteomics, metabolomics, synthetic biology)

By Application

• Healthcare/Medical Biotechnology
• Agricultural Biotechnology
• Industrial Biotechnology (bioenergy, bioplastics)
• Environmental Biotechnology (bioremediation, waste mgmt)
• Marine & Other Applications

By End User

• Pharma & Biotech Companies
• Academic & Research Institutions
• CROs & CDMOs
• Hospitals & Clinics

By Region

• Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Southeast Asia
• Australia 
• New Zealand